|Articles|December 15, 2004

Tauzin3

tauzin3

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

PharmTech Weekly Roundup—September 4, 2026

BySusan Haigney

September 4th 2026

The FDA clears zilganersen as the first disease-modifying Alexander disease drug, giving rare disease developers a blueprint for trial design and RNA delivery.

What an Alexander Disease Approval Means for RNA Developers

ByZachary Zubulake

September 4th 2026

AAPS PharmSci 360: CMC Strategies, Part 1

ByAlfred Rumondor, PhD,Swita Singh, PhD,Susan Haigney

September 2nd 2026

AAPS PharmSci 360: Microstructure Intelligence in Predictive Drug Development, Part 2

ByRobert Holt, PhD,Susan Haigney

September 2nd 2026

Medical award concept, winner cup on the desk | Image Credit: ©BillionPhotos.com -stock.adobe.com

CPHI Milan Names 2026 Pharma Awards Finalists

BySusan Haigney

September 1st 2026

Tauzin3

Related Content

PharmTech Weekly Roundup—September 4, 2026

What an Alexander Disease Approval Means for RNA Developers

AAPS PharmSci 360: CMC Strategies, Part 1

AAPS PharmSci 360: Microstructure Intelligence in Predictive Drug Development, Part 2

CPHI Milan Names 2026 Pharma Awards Finalists

Trending on Pharmaceutical Technology

CAR T-Cell Trial Pause Signals New Manufacturing Risk Review

CPHI Milan Names 2026 Pharma Awards Finalists

AAPS PharmSci 360: CMC Strategies, Part 1

What Novartis's $3.2 Billion Enzyme Licensing Deal Means for Formulation

Application of Predictive Modeling in the Development of Amorphous Solid Dispersions